Dementia Medicine by ‘Trojan horse’
Dementia Medicine by ‘Trojan horse’
  • Reporter Park Hee-won
  • 승인 2017.12.06 00:58
  • 댓글 0
이 기사를 공유합니다


▲ Alzeheimer's disease lesion cure effect
Scyllo-inositol, which exists in small amounts inside the human body, was an expected medicine to treat Alzheimer’s disease. It represses the condensation of β-amyloid protein that kills brain cells of Alzheimer patients. However, when administered in high concentrations, scyllo-inositol caused severe toxic nephrosis and failed in clinical demonstrations before the POSTECH research team. Professor Chung Sung-kee (CHEM) and Kim Kyong-Tai (IBB) found a way for medicine transporter to easily pass through the blood-brain-barrier that protects the brain between brain tissue and the brain capillary. They issued inventing ‘AAD-66’ that improved scyllo-inositol via an academic journal ‘Scientific Reports’.
The medicine is delivered to tissues and minimizes side-effects because a long term intake is needed. Due to a blood-brain-barrier that blocks the medicines absorption, most cure medicines were left as candidate materials. However, the research team had interest again in scyllo-inositol that everyone excluded as candidate. They expected a decent cure efficiency of scyllo-inositol, evading side-effects from high concentration injections. Prof. Chung explained that “By medicine transporter that overcomes blood-brain-barrier, the cure effect was improved. This result has significance because of the highly increased possibility of developing various materials to cure Alzheimer’s disease.”